Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D00SWQ
|
||||
| Former ID |
DNCL002891
|
||||
| Drug Name |
Mitoglitazone
|
||||
| Synonyms |
MSDC-0160; Mitoglitazone (TN)
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Type 2 diabetes [ICD9: 250; ICD10:E11] | Phase 2 | [523005] | ||
| Company |
Metabolic Solutions Development
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C19H18N2O4S
|
||||
| Canonical SMILES |
CCC1=CN=C(C=C1)C(=O)COC2=CC=C(C=C2)CC3C(=O)NC(=O)S3
|
||||
| InChI |
1S/C19H18N2O4S/c1-2-12-5-8-15(20-10-12)16(22)11-25-14-6-3-13(4-7-14)9-17-18(23)21-19(24)26-17/h3-8,10,17H,2,9,11H2,1H3,(H,21,23,24)
|
||||
| InChIKey |
IRNJSRAGRIZIHD-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Insulin receptor | Target Info | Modulator | [532846] | |
| KEGG Pathway | Ras signaling pathway | ||||
| Rap1 signaling pathway | |||||
| cGMP-PKG signaling pathway | |||||
| HIF-1 signaling pathway | |||||
| FoxO signaling pathway | |||||
| PI3K-Akt signaling pathway | |||||
| AMPK signaling pathway | |||||
| Adherens junction | |||||
| Insulin signaling pathway | |||||
| Ovarian steroidogenesis | |||||
| Type II diabetes mellitus | |||||
| Non-alcoholic fatty liver disease (NAFLD) | |||||
| Aldosterone-regulated sodium reabsorption | |||||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | ||||
| Pathway Interaction Database | Insulin Pathway | ||||
| Signaling events mediated by PTP1B | |||||
| Signaling events mediated by TCPTP | |||||
| Insulin-mediated glucose transport | |||||
| PathWhiz Pathway | Insulin Signalling | ||||
| Leucine Stimulation on Insulin Signaling | |||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.